drugset / Trial / NCT01677377

Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

NCT01677377

Phase 2 Completed 45 enrolled Indivior Inc.
Non-randomizedFactorialOpen-labelTreatment

Summary

Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia

Timeline

Start
2012-08
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 60 mg Subcutaneous
Subject Risperidone Other / unclassified 90 mg Subcutaneous
Subject Risperidone Other / unclassified 120 mg Subcutaneous
Subject Risperidone Other / unclassified 2 mg Oral
Subject Risperidone Other / unclassified 3 mg Oral
Subject Risperidone Other / unclassified 4 mg Oral

Indications